Find out more ways to treat psoriasis in the future

Published Date: 02 Mar 2023

According to MBA MD Andrew Blauvelt, the development of oral biologics and early treatment to replace the disease is a possibility.

Read Full News

Latest News

Consensus Defines Vitiligo Severity, Relapse Beyond BSA

An international consensus study establishes standardized definitions for vitiligo severity and relapse, emphasizing that body surface area alone is insufficient to capture disease burden.

First-Line Biologics May Improve Psoriasis Outcomes

Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.

Pfizer-Valneva Lyme Vaccine Shows More Than 70% Efficacy but Misses Key Goal

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, ⁠even as it missed its main goal.

Can Mpox Vaccine Immunity Last for 5 Years?

The modified vaccinia Ankara-Bavarian Nordic vaccine induces sustained immune memory for up to 5 years, and a single booster dose at 5 years sharply raises antibody levels, a prospective study shows.

FDA Approves Dermal Filler for Temple Hollowing Indication

Loss of temple volume may be accelerated in people rapidly losing weight with medication.

Higher Mortality Risk Seen in axSpA, PsA in Real-World Study

Patients with axial spondyloarthritis and psoriatic arthritis face an elevated risk for all-cause mortality compared with the general population, and the risk is reduced with b/tsDMARD treatment.

Todays Updates

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Todays Updates

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Latest News

An international consensus study establishes standardized definitions for vitiligo severity and relapse, emphasizing that body surface area alone is insufficient to capture disease burden.

Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, ⁠even as it missed its main goal.

The modified vaccinia Ankara-Bavarian Nordic vaccine induces sustained immune memory for up to 5 years, and a single booster dose at 5 years sharply raises antibody levels, a prospective study shows.

Loss of temple volume may be accelerated in people rapidly losing weight with medication.

Patients with axial spondyloarthritis and psoriatic arthritis face an elevated risk for all-cause mortality compared with the general population, and the risk is reduced with b/tsDMARD treatment.

News All Time

Low-Beta Radiation Patch Offers Alternative NMSC Treatment

Similar to brachytherapy, OncoPatch could be an option for patients who have superficial lesions or who aren’t surgical candidates.

What Does FDA Food Pyramid Mean for Cancer Risk and Care?

Much of the new FDA food guidance aligns with existing advice, but some areas may introduce confusion to advising patients on diet and cancer prevention and survival.

UK Approves New JAK Inhibitor for Severe Alopecia

Deuruxolitinib is the latest JAK inhibitor to enter the UK alopecia areata treatment landscape, pending a NICE decision on NHS access.

Tildrakizumab Now Under FDA Review for Psoriatic Arthritis

Full results from the pivotal trials submitted to support approval have not yet been reported.

Early Intensive Therapy Best for PsA With Poor Prognosis

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes were maintained at 48 weeks in the TNFi group.

Guselkumab Effective After TNF Inhibitor Failure in PsA

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

Meta-analysis: Dermoscopic Features Distinguish ALM

Parallel ridge and multicomponent patterns are the most common dermoscopic features that identify acral lentiginous melanoma, according to a meta-analysis.

Geriatric Oncology Has Become Personalized: Here’s Why

As immunotherapy reshaped cancer care, geriatric oncology shifted toward personalized, geriatric assessment-guided treatment that prioritizes function, safety, and what matters most to older adults.

Hidradenitis Suppurativa Raises Risk for Self-Harm, Suicide

Patients with hidradenitis suppurativa have a higher risk for self-harm and suicide than matched control individuals, according to the results of a Danish cohort study.

Perianal Abscess Tied to Crohn's Disease Risk in Older Kids

Older children with perianal abscess or fistula-in-ano, especially those with recurrent perianal abscess or fistula-in-ano or gastrointestinal symptoms, are more likely to develop Crohn's disease.

Bimekizumab Not Tied to Mental Health Risk, Study Suggests

A study suggests that bimekizumab does not increase the risk for depression or suicidal ideation compared with IL-23 inhibitors in adults with psoriasis.

Should Biology Replace Organ Labels in Cancer Treatment?

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

PIP Matches PrEP for Low-Risk HIV

The use of medicine at home offers convenience and curbs costs.

Can Physical Activity Improve Skin Cancer Outcomes?

Physical activity is associated with a reduced risk for all-cause mortality and improved survival in patients with skin cancer, a meta-analysis shows.

Healthy Diet May Cut Cancer Survivors’ Premature Aging Risk

A recent study found reduced premature aging among childhood cancer survivors that adhered to established dietary guidelines.

AI Tools Helpful With Prior Auth Letters, Handouts, and More

‘Specify everything you need, do it as if you’re talking to your medical assistant,’ one dermatologist recommends.

Recommended News For You

Papillary thyroid cancer: New markers offer hope for tailored treatment

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.

How a California Oncologist Making $850k Spends Money

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

Recommended Articles For You

Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025 

An Analytical and Statistical Journey through Genomic Revolution, Novel Therapeutics, and Future Horizons in Lymphoma 2025 

The benefits and risks of taking fludrocortisone for adrenal insufficiency  

HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

2.

The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.

3.

Investigating the Relationship Between GERD and Anxiety/Depression.

4.

Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds

5.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

1.

Understanding Axitinib: What You Need To Know For Your Treatment Plan

2.

All You Need To Know About Partial Thromboplastin Time (PTT) Test

3.

Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential

4.

Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes

5.

Polyposis Syndrome: Causes, Symptoms, and Treatment Options

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

3.

Navigating the Complexities of Ph Negative ALL - Part XI

4.

Updates on the First Line Management of ALK+ NSCLC

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot